DAVID C YOUNG portrait
  • Multi-state Pharmacy Jurisprudence Examination (MPJE) Committee, National Association of Boards of Pharmacy (NABP)
  • Vice Chair, Pharmacotherapy
  • Controlled Substances Advisory Committee, Division of Occupational & Professional Licensing (DOPL)
  • Cystic Fibrosis Related Diabetes (CFRD) Guideline Committee, Cystic Fibrosis Foundation
  • Utah Asthma Task Force, Utah Department of Health
  • Coordinator of Student Affairs, College Of Pharmacy
  • Adjunct Professor, Physical Therapy & Athletic Training
  • Professor (Clinical), Pharmacotherapy

Research Keywords

  • Rhinitis, Allergic, Perennial
  • Pulmonary Disease, Chronic Obstructive
  • GERD
  • Cystic Fibrosis
  • Asthma, Exercise-Induced
  • Asthma Management
  • Asthma
  • Anti-Asthmatic Agents

Presentations

  • “Asthma and the Breath of Life”, Presented at the Essentials of Correctional Medicine Conference, Salt Lake City, Utah, November 2012 . Invited Talk/Keynote, Accepted, 11/07/2012.
  • “Pharmacists Collaborating to Optimize Anti-staphylococcal and Anti-pseudomonal Antibiotic Utilization in CF”, Presented at the North American Cystic Fibrosis Conference Orlando, Florida, October 2012 (Pharmacist Caregiver Session). Invited Talk/Keynote, Presented, 10/11/2012.
  • “Advanced Drug Therapy for the Treatment of Acute Pulmonary Exacerbations”, Presented at the North American Cystic Fibrosis Conference Orlando, Florida, October 2012 (Short Course; Lead Instructor). Invited Talk/Keynote, Presented, 10/10/2012.
  • “Pharmacy Based Immunization Delivery—A certificate program for pharmacists” Presented at the University of Utah College of Pharmacy, Salt Lake City, Utah, August 2012 . Invited Talk/Keynote, Presented, 08/31/2012.
  • “Maximizing Benefit/Minimizing Risk: PK-PD Considerations of Antipseudomonal Antibiotics”, Presented at the North American Cystic Fibrosis Conference Anaheim, California, November 2011 (Symposium Speaker). Invited Talk/Keynote, Presented, 11/04/2011.
  • “Maximizing Benefit/Minimizing Risk: PK-PD Considerations of Antipseudomonal Antibiotics”, Presented at the North American Cystic Fibrosis Conference Anaheim, California, November 2011 (Symposium Speaker). Invited Talk/Keynote, Presented, 11/04/2011.
  • Jeffery T. Zobell, Pharm.D., Chris Stockmann, Ph.D.; David C. Young, Pharm.D.; Jared Cash, Pharm.D., BCPS; Catherine Sherwin, Ph.D.; Mike Spigarelli, M.D., Ph.D.; Barbara A. Chatfield, MD; Krow Ampofo, M.D. Population pharmacokinetics (PK) and pharmacodynamics (PD) modeling of ticarcillin-clavulanate in pediatric CF patients. Pediatr Pulmonol 2011 Oct; Suppl 34: 277 . Poster, Presented, 11/04/2011.
  • “Strategies to Implementation of a Dedicated Pharmacist to the CF Team”, Presented at the North American Cystic Fibrosis Conference Anaheim, California, November 2011 (Pharmacist Caregiver Session). Invited Talk/Keynote, Presented, 11/03/2011.
  • “Strategies to Implementation of a Dedicated Pharmacist to the CF Team”, Presented at the North American Cystic Fibrosis Conference Anaheim, California, November 2011 (Pharmacist Caregiver Session). Invited Talk/Keynote, Presented, 11/03/2011.
  • “Pharmacy Based Immunization Delivery—A certificate program for pharmacists” Presented at the University of Utah College of Pharmacy, Salt Lake City, Utah, August 2011 . Invited Talk/Keynote, Presented, 08/19/2011.
  • “Your Asthma Device & You: a hands on approach” Presented at the University of Utah Alumni Association Summer CE. Cedar City, Utah, June 2011. Invited Talk/Keynote, Presented, 08/06/2011.
  • “The Last Chance for the Latest Law Update” Presented at the University of Utah Alumni Association Summer CE. Cedar City, Utah, August 2011. Invited Talk/Keynote, Presented, 08/06/2011.
  • “In the World of Asthma, Device Matters” Presented as webinar for the UtahTelehealth Network. Salt Lake City, Utah, May 2011. Invited Talk/Keynote, Presented, 05/01/2011.
  • “Utah Law Update” Presented at the University of Southern Nevada Spring CE. Moab, Utah, March 2011. Invited Talk/Keynote, Presented, 03/02/2011.
  • “Utah Law Update” Presented at the University of Southern Nevada Spring CE. South Jordan, Utah, March 2011. Invited Talk/Keynote, Presented, 03/01/2011.
  • “End of Life Ethics Panel” Presented at the Utah Society of Health Systems Pharmacists Mid-Winter Meeting. Salt Lake City, Utah, February 2011. Invited Talk/Keynote, Presented, 02/01/2011.
  • “Pediatric vs Adult Asthma: What is the difference. Presented on Utah Telehealth Network as Asthma Telehealth Series live webcast. Salt Lake City, Utah, November 2010 . Invited Talk/Keynote, Presented, 11/17/2010.
  • “Asthma Update-The Need to Breathe” Presented at the Utah Society of Health Systems Pharmacists Annual Meeting. Layton, Utah, October 2010. Invited Talk/Keynote, Presented, 10/09/2010.
  • “New Treatment Regimens in CF: Extended Interval Antibiotics” Presented at Montana Cystic Fibrosis Center Annual Conference, Billings, Montana, October 2010. Invited Talk/Keynote, Presented, 09/25/2010.
  • “Utah Law Update-The only constant is change” Presented at Primary Children’s Medical Center. Salt Lake City, Utah, September 2010. Invited Talk/Keynote, Presented, 09/16/2010.
  • “Pharmacy Based Immunization Delivery—A certificate program for pharmacists” Presented at the University of Utah College of Pharmacy, Salt Lake City, Utah, August 2010. Panel, Presented, 08/20/2010.
  • “Utah Law Update-The only constant is change” Presented at the University of Utah Alumni Association Summer CE. Cedar City, Utah, August 2010. Invited Talk/Keynote, Presented, 08/07/2010.

Grants, Contracts & Research Gifts

  • Comparative Effectiveness of Dual Bronchodilation for Treatment of Chronic Obstructive Pulmonary Disorder (COPD) in a Usual-Care Setting . PI: Asche Carl V. Co-PI(s): Young David, Yu Junhua, Ye Xiangyang, Oberg Brian. Novartis Pharmaceuticals , 04/09/2009 - 05/31/2010. Total project budget to date: $299,798.00
  • Impact of individualized, pharmacist-provided asthma education in an Asthma Care Pharmacy . PI: David Young. Co-PI(s): Zobell J, Jorgensen R, Jennings B, Wagner D, Jolley T, Atherton A, Fitzpatrick R, Samuelson W. Marriner S Eccles Foundation, 03/31/2009 - present. Total project budget to date: $6,500.00
  • COPD: Impact of Intervention on Compliance to the recommended HEDIS guidelines, Clinical Outcomes and Cost of Illness. PI: Asche C. Co-PI(s): Brixner D, Young D. Boehringer-Ingelheim , 06/01/2006 - present. Total project budget to date: $153,000.00
  • Elucidation of Acid-Induced Pulmonary Inflammation. PI: Peterson K. Co-PI(s): Samuelson W, Go M, Young DC, Sturrock A, Kuwada S, Ryujin D. Tap Pharmaceutical Products Inc, 07/01/2005 - present. Total project budget to date: $111,345.00

Languages

  • English, fluent.

Publications

  • David C. Young, Pharm.D.; Jeffery T. Zobell, Pharm.D.; Dustin Waters, Pharm.D.; Krow Ampofo, M.D.; Chris Stockmann, MSc; Catherine M.T. Sherwin, Ph.D.; Michael Spigarelli, M.D., Ph.D. Optimization of Anti-pseudomonal Antibiotics for CysticFibrosis Pulmonary Exacerbations: IV. Colistimethate sodium. Pediatric Pulmonol. 2012 (DOI: 10.1002/ppul.22664). Published, 09/04/2012.
    http://onlinelibrary.wiley.com/doi/10.1002/ppul.22...
  • Chris Stockmann, MSc; Catherine M.T. Sherwin, Ph.D.; Jeffery T. Zobell, Pharm.D.; David C. Young, Pharm.D.; Dustin Waters, Pharm.D.; Michael Spigarelli, M.D., Ph.D.; Krow Ampofo, M.D. Optimization of Anti-pseudomonal Antibiotics for CysticFibrosis Pulmonary Exacerbations: III. Fluoroquinolones. Pediatric Pulmonol. 2012 (DOI: 10.1002/ppul.22667). Published, 09/04/2012.
    http://onlinelibrary.wiley.com/doi/10.1002/ppul.22...
  • Jeffery T. Zobell, Pharm.D.; Dustin Waters, Pharm.D.; David C. Young, Pharm.D.; Chris Stockmann, MSc; Krow Ampofo, M.D.; Catherine M.T. Sherwin, Ph.D.; Michael Spigarelli, M.D., Ph.D. Optimization of Anti-pseudomonal Antibiotics for CysticFibrosis Pulmonary Exacerbations: II. Penicillins and Cephalosporins. Pediatric Pulmonol. 2012 (DOI: 10.1002/ppul.22669). Published, 09/04/2012.
    http://onlinelibrary.wiley.com/doi/10.1002/ppul.22...
  • Jeffery T. Zobell, Pharm.D.; Dustin Waters, Pharm.D.; David C. Young, Pharm.D.; Chris Stockmann, MSc; Krow Ampofo, M.D.; Catherine M.T. Sherwin, Ph.D.; Michael Spigarelli, M.D., Ph.D. Optimization of Anti-pseudomonal Antibiotics for CysticFibrosis Pulmonary Exacerbations: I. Aztreonam and Carbapenems. Pediatric Pulmonol. 2012 (DOI: 10.1002/ppul.22655). Published, 08/21/2012.
    http://onlinelibrary.wiley.com/doi/10.1002/ppul.22...
  • 1. Carl Victor Asche, Shelah Leader, Craig Plauschinat, Ming Yan, Xiangyang Ye, David C. Young. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids. International Journal of COPD 2012;7:201-209. Published, 03/14/2012.
    http://www.dovepress.com/articles.php?article_id=9...
  • David C. Young, Pharm.D. Maximizing Benefit/Minimizing Risk: PK-PD Considerations of Antipseudomonal Antibiotics. Pediatr Pulmonol 2011 Oct; Suppl 34: 155. Published, 11/03/2011.
  • Jeffery T. Zobell, Pharm.D., Chris Stockmann, Ph.D.; Krow Ampofo, MD; David C. Young, Pharm.D.; Jared Cash, Pharm.D., BCPS; Brittany J. McDowell, Kent Korgenski, MS,MT(ACSP); Barbara A. Chatfield, MD. Pharmacodynamic Modeling of High Dose Intermittent Ticarcillin-clavulanate Administration In Pediatric Cystic Fibrosis Patients. Clinical Therapeutics 2011 Jul;9(4):280-3. Published, 10/21/2011.
    http://dx.doi.org/10.1016/j.clinthera.2011.09.010
  • Jeffery T. Zobell, Pharm.D., David C. Young, Pharm.D., C. Dustin Waters, Pharm.D., BCPS, Krow Ampofo, M.D., Jared Cash, Pharm.D., BCPS, Bruce C. Marshall, M.D., Jared Olson, Pharm.D., and Barbara A. Chatfield, M.D. A Survey of the Utilization of Anti-Pseudomonal Beta-Lactam Therapy in Cystic Fibrosis Patients. Pediatric Pulmonology 2011;46:987-990. Published, 04/25/2011.
    http://onlinelibrary.wiley.com/doi/10.1002/ppul.21...
  • High dose intermittent ticarcillin–clavulanate administration in pediatric cystic fibrosis patients 
Jeffery T. Zobell, Krow Ampofo, Jared Cash, Kent Korgenski, Barbara A. Chatfield (Acknowledgements Young DC)
Journal of Cystic Fibrosis - July 2010; Vol. 9, Issue 4, Pages 280-283. Published, 07/01/2010.
  • The role of gastroesophageal reflux in exercise-triggered asthma: a randomized controlled trial. Peterson KA, Samuelson WM, Ryujin DT, Young DC, Thomas KL, Hilden K, Fang JC. Dig Dis Sci. 2009 Mar;54(3):564-71. Epub 2008 Aug 8. PMID: 18688720 [PubMed - indexed for MEDLINE]. Published, 03/01/2009.
    http://www.ncbi.nlm.nih.gov/pubmed/18688720